TELA supply chain intelligence for TELA Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BDX | Becton, Dickinson and Company | 72% | Reciprocal relationship from BDX graph: Reciprocal relationship from TELA graph: cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal t… |
| BDX | Becton, Dickinson and Company | 72% | cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal to 27% of our net sales of our OviTex and OviTex PRS products, with the exception … |
| MDT | Medtronic plc | 72% | rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology companies such as Orthovita Inc., Stryker Corporation, OraSure Technolo… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from TELA graph: Reciprocal relationship from MDT graph: Reciprocal relationship from TELA graph: rgeon adoption of biologic and biosur… |
| MDXG | MiMedx Group, Inc. | 72% | cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal to 27% of our net sales of our OviTex and OviTex PRS products, with the exception … |
| MDXG | MiMedx Group, Inc. | 72% | Reciprocal relationship from MDXG graph: Reciprocal relationship from TELA graph: cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal … |
| OSUR | OraSure Technologies, Inc. | 72% | Reciprocal relationship from OSUR graph: Reciprocal relationship from TELA graph: rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical … |
| OSUR | OraSure Technologies, Inc. | 72% | rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology companies such as Orthovita Inc., Stryker Corporation, OraSure Technolo… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $45,415 across 5 awards. 36C24225P0099 SURGICAL IMPLANT; 36C26126P0059 PROSTHETICS - MESH; 36C25025P1056 OVITEX 1S PERMANENT 25X30 | Qwen corre… |
| GPOS | GPOS | 90% | We have contracted with three national GPOs covering our OviTex and OviTex PRS products |
| HOSPITALS | HOSPITALS | 90% | A significant portion of the Company’s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. |
| SURGICAL-FACILITIES | SURGICAL-FACILITIES | 90% | A significant portion of the Company’s revenue is generated from product shipped to a customer or from consigned inventory maintained at hospitals or other surgical facilities. |
| HEALTHCARE-SYSTEMS | HEALTHCARE-SYSTEMS | 85% | Our OviTex products are sold at prices approximately 20% to 40% lower than other biologic matrices and resorbable synthetic mesh |
| THIRD-PARTY-PAYORS | THIRD-PARTY-PAYORS | 85% | The Company enters into contracts with certain third-party payors for the payment of rebates with respect to the utilization of its products. |
| BDX | Becton, Dickinson and Company | 72% | Reciprocal relationship from BDX graph: Reciprocal relationship from TELA graph: cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal t… |
| BDX | Becton, Dickinson and Company | 72% | cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal to 27% of our net sales of our OviTex and OviTex PRS products, with the exception … |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from TELA graph: rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical t… |
| MDT | Medtronic plc | 72% | rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology companies such as Orthovita Inc., Stryker Corporation, OraSure Technolo… |
| MDXG | MiMedx Group, Inc. | 72% | Reciprocal relationship from MDXG graph: Reciprocal relationship from TELA graph: cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal … |
| MDXG | MiMedx Group, Inc. | 72% | cost as a percentage of Aroa’s cost of goods sold, and subject to a true-up adjustment, resulting in an amount equal to 27% of our net sales of our OviTex and OviTex PRS products, with the exception … |
| OSUR | OraSure Technologies, Inc. | 72% | rgeon adoption of biologic and biosurgery technologies. Members of our team have held leading positions with medical technology companies such as Orthovita Inc., Stryker Corporation, OraSure Technolo… |
| OSUR | OraSure Technologies, Inc. | 72% | Reciprocal relationship from OSUR graph: Reciprocal relationship from TELA graph: Reciprocal relationship from OSUR graph: Reciprocal relationship from TELA graph: Reciprocal relationship from OSUR g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TELA-DEBT | Debt stack $55.9M | 90% | Market cache reports total debt of $55.9M. |
| TELA-DEBT-12934 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| TELA-DEBT-12933 | Warrants outstanding: 1413000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TELA-OWNER-ESSEX-WOODLANDS-MANAGEMENT-INC | Essex Woodlands Management, Inc. | 90% | 13F overlay lists Essex Woodlands Management, Inc. as top holder; 38 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| NDRA | ENDRA Life Sciences Inc. | 100.00 | 2 | |
| PLSE | Pulse Biosciences, Inc. | 100.00 | 2 | |
| PYPD | PolyPid Ltd. | 100.00 | 2 | |
| NAUT | Nautilus Biotechnology, Inc. | 100.00 | 2 | |
| IART | Integra LifeSciences Holdings Corporation | 100.00 | 2 | |
| OBIO | Orchestra BioMed Holdings, Inc. | 100.00 | 2 | |
| SSII | SS Innovations International, Inc. | 100.00 | 2 | |
| STQN | Strategic Acquisitions, Inc. | 100.00 | 2 | |
| ISRG | Intuitive Surgical, Inc. | 100.00 | 2 | |
| ANGO | AngioDynamics, Inc. | 100.00 | 2 | |
| CDNA | CareDx, Inc. | 100.00 | 2 | |
| EW | Edwards Lifesciences Corporation | 100.00 | 2 | |
| NPCE | NeuroPace, Inc. | 100.00 | 2 | |
| HBIO | Harvard Bioscience, Inc. | 100.00 | 2 | |
| IINN | Inspira Technologies Oxy B.H.N. Ltd. | 100.00 | 2 | |
| EMBC | Embecta Corp. | 100.00 | 2 | |
| WAT | Waters Corporation | 100.00 | 2 | |
| GWW | W.W. Grainger, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| XTNT | Xtant Medical Holdings, Inc. | 100.00 | 2 |